CuII (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease.

Adam SouthonKathryn SzostakKarla M AcevedoKrista A DentIrene VolitakisAbdel A BelaidiKevin J BarnhamPeter J CrouchScott Jonathan AytonPaul S DonnellyAshley I Bush

Published in: British journal of pharmacology (2020)

The antiferroptotic activity of CuII (atsm) could therefore be the disease-modifying mechanism being tested in ALS and PD trials. With potency in vitro approaching that of liproxstatin-1, CuII (atsm) possesses favourable properties such as oral bioavailability and entry into the brain that make it an attractive investigational product for clinical trials of ferroptosis-related diseases.

Keyphrases

cell death
clinical trial
phase ii
resting state
randomized controlled trial
cerebral ischemia
open label
functional connectivity